KalVista Pharmaceuticals (KALV) News Today

Marshall Wace LLP lowered its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 92.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 48,911 shares of the specialty pharmaceutical company's s

Dimensional Fund Advisors LP trimmed its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 7.7% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 534,979 shares of the specialty pharmaceutical company's stock after selling 44,680 sha

HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Monday.

Susquehanna Fundamental Investments LLC increased its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 323.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 68,526 shares of the specialty pharmaceutica

Great Point Partners LLC acquired a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,338,568 shares of the specialty pharmaceutical comp

First Turn Management LLC trimmed its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 10.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,059,540 shares of the specialty pharmaceutica

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 7,352 shares of the business's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $12.19, for a total value of $89,620.88. Following the completion of the transaction, the chief executive officer now owns 250,800 shares in the company, valued at approximately $3,057,252. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Cantor Fitzgerald reiterated an "overweight" rating on shares of KalVista Pharmaceuticals in a research note on Monday.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Investment analysts at Leerink Partnrs issued their FY2026 earnings per share (EPS) estimates for shares of KalVista Pharmaceuticals in a research note issued on Thursday, September 5th. Leerink Partnrs analyst J. Schwartz forecasts tha

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) issued its earnings results on Thursday. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.91) by $0.04.

Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday.

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 9.3%

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a report issued on Monday, August 26th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the specialty pharmaceutical compa

Cantor Fitzgerald upgraded KalVista Pharmaceuticals to a "strong-buy" rating in a report on Monday.

AlphaCentric Advisors LLC trimmed its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 98.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,500 shares of

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul K. Audhya sold 2,135 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $12.40, for a total transaction of $26,474.00. Following the completion of the sale, the insider now owns 83,745 shares in the company, valued at $1,038,438. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

KalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 4.4%

Vanguard Group Inc. decreased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 5.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,685,113 shares of the specialty

KalVista Pharmaceuticals (NASDAQ:KALV) Share Price Passes Above 50 Day Moving Average of $12.80

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totalling 6,330,000 shares, an increase of 7.7% from the June 30th total of 5,880,000 shares. Based on an average trading volume of 343,500 shares, the days-to-cover ratio is currently 18.4 days.

Capital World Investors purchased a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,464,606 shares of the specialty pharmaceutical company's stock, valued at appro

SG Americas Securities LLC lessened its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 91.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,082 shares of the specialty pharmaceutical company's stoc

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Research analysts at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for shares of KalVista Pharmaceuticals in a report released on Monday, July 15th. HC Wainwright analyst A. Fein now forecasts that the specialty pha

KalVista Pharmaceuticals (NASDAQ:KALV) Trading 4% Higher